Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status (Descending)
70771-1185-00 70771-1185 Tamoxifen Citrate Tamoxifen Citrate 20.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Jan. 3, 2018 In Use
70771-1185-01 70771-1185 Tamoxifen Citrate Tamoxifen Citrate 20.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Jan. 3, 2018 In Use
70771-1185-03 70771-1185 Tamoxifen Citrate Tamoxifen Citrate 20.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Jan. 3, 2018 In Use
70771-1185-04 70771-1185 Tamoxifen Citrate Tamoxifen Citrate 20.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Jan. 3, 2018 Dec. 5, 2019 In Use
70771-1185-05 70771-1185 Tamoxifen Citrate Tamoxifen Citrate 20.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Jan. 3, 2018 Dec. 5, 2019 In Use
70771-1185-06 70771-1185 Tamoxifen Citrate Tamoxifen Citrate 20.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Jan. 3, 2018 In Use
70771-1185-09 70771-1185 Tamoxifen Citrate Tamoxifen Citrate 20.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Jan. 3, 2018 In Use
70518-3070-00 70518-3070 Medroxyprogesterone Acetate Medroxyprogesterone Acetate 10.0 mg/1 Hormonal Therapy Progestin Oral April 10, 2021 Sept. 1, 2021 In Use
70518-3070-01 70518-3070 Medroxyprogesterone Acetate Medroxyprogesterone Acetate 10.0 mg/1 Hormonal Therapy Progestin Oral Nov. 11, 2021 In Use
00378-3096-85 00378-3096 Everolimus Everolimus 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Dec. 15, 2022 In Use
00378-3098-85 00378-3098 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Dec. 15, 2022 In Use
00781-3253-94 00781-3253 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Sept. 16, 2013 Feb. 28, 2025 In Use
16729-0131-30 16729-0131 FLUDARABINE FLUDARABINE PHOSPHATE 25.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Nov. 22, 2022 In Use
42858-0869-06 42858-0869 DRONABINOL DRONABINOL 10.0 mg/1 Ancillary Therapy Antiemetic CB1/CB2 Oral June 26, 2018 In Use
71288-0112-90 71288-0112 Melphalan hydrochloride Melphalan hydrochloride Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous June 30, 2019 April 30, 2025 In Use
76961-0101-01 76961-0101 Eflapegrastim-xnst Rolvedon 13.2 mg/.6mL Ancillary Therapy Immunostimulant Granulocyte colony stimulating factor Subcutaneous Oct. 18, 2022 In Use
00480-5425-89 00480-5425 Sorafenib Sorafenib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, RET/PTC, CRAF, BRAF Oral Jan. 3, 2023 In Use
10019-0079-01 10019-0079 Bendamustine hydrochloride BENDAMUSTINE HYDROCHLORIDE 100.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec. 15, 2022 In Use
55150-0384-01 55150-0384 Triamcinolone Acetonide Triamcinolone Acetonide 40.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-articular, Intramuscular, Soft Tissue July 5, 2022 In Use
55150-0385-01 55150-0385 Triamcinolone Acetonide Triamcinolone Acetonide 40.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-articular, Intramuscular, Soft Tissue July 5, 2022 In Use
55150-0393-01 55150-0393 AZACITIDINE AZACITIDINE 100.0 mg/4mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Jan. 3, 2023 In Use
60760-0654-10 60760-0654 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 22, 2022 In Use
61703-0124-40 61703-0124 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intramuscular, Intrathecal, Intravenous, Subcutaneous Jan. 9, 2023 In Use
70518-3612-00 70518-3612 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Jan. 8, 2023 In Use
70518-3615-00 70518-3615 HYDROXYUREA HYDROXYUREA 500.0 mg/1 Chemotherapy Miscellaneous Agent Antimetabolite/Organooxygen Oral Jan. 10, 2023 In Use
71288-0145-10 71288-0145 Pemetrexed disodium Pemetrexed 100.0 mg/4.2mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Dec. 13, 2022 In Use
71288-0146-50 71288-0146 Pemetrexed disodium Pemetrexed 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Dec. 13, 2022 In Use
71288-0147-50 71288-0147 Pemetrexed disodium Pemetrexed 750.0 mg/30mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Dec. 13, 2022 In Use
71288-0148-51 71288-0148 Pemetrexed disodium Pemetrexed 1.0 g/40mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Dec. 13, 2022 In Use
72851-0042-01 72851-0042 Leuprolide CAMCEVI 42.0 mg/mL Hormonal Therapy GnRH Agonist Subcutaneous Dec. 30, 2022 In Use
80425-0074-04 80425-0074 Ondansetron HCL Ondansetron HCL 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 16, 2020 In Use
80425-0074-01 80425-0074 Ondansetron HCL Ondansetron HCL 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 16, 2020 In Use
80425-0074-02 80425-0074 Ondansetron HCL Ondansetron HCL 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 16, 2020 In Use
80425-0074-03 80425-0074 Ondansetron HCL Ondansetron HCL 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 16, 2020 In Use
80425-0074-05 80425-0074 Ondansetron HCL Ondansetron HCL 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sept. 16, 2020 In Use
80425-0222-01 80425-0222 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 12, 2023 In Use
80425-0227-01 80425-0227 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 11, 2023 In Use
80739-0812-12 80739-0812 Adagrasib KRAZATI 200.0 mg/1 Immunotherapy RAS Inhibitor KRAS G12C Oral Dec. 12, 2022 In Use
80739-0812-18 80739-0812 Adagrasib KRAZATI 200.0 mg/1 Immunotherapy RAS Inhibitor KRAS G12C Oral Dec. 12, 2022 In Use
50242-0159-01 50242-0159 Mosunetuzumab Lunsumio 1.0 mg/mL Immunotherapy Monoclonal Antibody CD20, CD3 Intravenous Dec. 22, 2022 In Use
50242-0142-01 50242-0142 Mosunetuzumab Lunsumio 30.0 mg/30mL Immunotherapy Monoclonal Antibody CD20, CD3 Intravenous Dec. 22, 2022 In Use
00378-3097-85 00378-3097 everolimus everolimus 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Dec. 15, 2022 In Use
16714-0671-01 16714-0671 Ondansetron Hydrochloride Ondansetron 4.0 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Nov. 28, 2007 Oct. 31, 2016 In Use
16714-0671-02 16714-0671 Ondansetron Hydrochloride Ondansetron 4.0 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Nov. 28, 2007 In Use
50090-0091-00 50090-0091 Dexamethasone Dexamethasone 4.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Nov. 28, 2014 In Use
50090-2098-00 50090-2098 Methylprednisolone Acetate Depo-Medrol 40.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-Articular, Intralesional, Intramuscular, Soft Tissue Oct. 13, 2015 In Use
50242-0918-01 50242-0918 Atezolizumab TECENTRIQ 840.0 mg/14mL Immunotherapy Checkpoint Inhibitor PD-L1 Intravenous March 8, 2019 In Use
50242-0918-86 50242-0918 Atezolizumab TECENTRIQ 840.0 mg/14mL Immunotherapy Checkpoint Inhibitor PD-L1 Intravenous March 8, 2019 March 18, 2019 In Use
51991-0005-33 51991-0005 Exemestane Exemestane 25.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral Dec. 19, 2019 Dec. 31, 2022 In Use
51991-0005-90 51991-0005 Exemestane Exemestane 25.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral Nov. 15, 2020 In Use

Found 10,000 results in 6 millisecondsExport these results